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A B S T R A C T   
Injection of antigenic peptides has been widely used as a vaccine strategy to boost T cell immunity. However, the 
poor immunogenicity of single peptides can potentially be strengthened through modification of the tertiary 
structure and the selection of the accompanying adjuvant. Here, we generated antigenic peptides into non-linear 
trimers by solid phase peptide synthesis, thereby enhancing antigen presentation by dendritic cells to CD8 T 
cells in vitro and in vivo. CD8 T cells from mice vaccinated with trimers showed an KLRG1 effector phenotype 
and were able to recognize and kill antigen-expressing tumor cells ex vivo. Importantly, trimers outperformed 
synthetic long peptide in terms of T cell response even when equal number of epitopes were used for immuni-
zation. To improve the synthesis of trimers containing difficult peptide sequences, we developed a novel small 
molecule that functions as conjugation platform for synthetic long peptides. This platform , termed Antigen 
MAtriX (AMAX) improved yield, purity and solubility of trimers over conventional solid phase synthesis stra-
tegies. AMAX outperformed synthetic long peptides in terms of both CD8 and CD4 T cell responses and 
allowed functionalization with DC-SIGN-binding carbohydrates for in vivo dendritic cell targeting strategies, 
boosting T cell responses even further. Moreover, we show that agonistic CD40 antibody combined with MF59 
(AddaVax) emulsion synergistically improves the antigen-specific T cell response of the AMAX in vivo. Also, 
tumor-associated antigens and neo-antigens could be incorporated in AMAX for tumor-specific CD8 T cell re-
sponses. Importantly, immunization with a mix of neoantigen AMAX could reduce tumor growth in a pre-clinical 
syngeneic mouse model. Hence, we provide pre-clinical support for the induction of effector CD8 T cells 
through the adaptable AMAX platform as easy implementable peptidic vaccination strategy against any antigen 
of choice, including neoantigens for anti-tumor immunity.   
1. Introduction 
T cell-mediated immune responses can protect the host against 
intracellular pathogens, non-functional cells and transformed cells, like 
tumor cells. The ability of the immune system to recognize and deal with 
these host-damaging processes is dependent on antigens presented on 
MHC class I (MHCI). While the host is generally capable of inducing 
these antigen-specific responses upon infection, artificial inducers of 
immunity like vaccines can initiate these responses in absence of 
damaging pathogens. Tumor- and pathogen-associated antigens in the 
form of peptides can be used in vaccines to induce antigen-specific im-
mune responses. However, peptidic vaccines are inherently of low 
immunogenicity and are therefore often coupled to immunogenic carrier 
proteins like keyhole limpet hemocyanin (KLH) or formaldehyde- 
inactivated diphtheria toxoid (DT) [1]. Synthetic long peptides can 
additionally be conjugated to poly-lysine cores into dendrimers with 
high molecular weight, called multiple peptide antigen systems (MAPs) 
[2]. Another approach is to chemically synthesize antigens in the form of 
long peptides and combine these with innate immune stimuli like ad-
juvants [3]. Using active immunotherapy with carefully determined 
antigenic peptides ensures both rapid effector phases of immunity as 
well as the formation of immunological memory needed for prolonged 
disease-free conditions. 
In the era of genomic-based antigen discovery and high throughput 
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mass spectrometry, the antigens presented by infected or malignant cells 
are increasingly being identified and exploited for vaccine design [4,5]. 
For example, by isolating MHCI-bound peptides of glioblastoma tumor 
tissue and subsequently performing liquid chromatography–mass spec-
trometry (LC-MS), shared antigens expressed specifically by glioblas-
toma in tumor patients can be identified [6]. Using these 
glioblastoma-specific antigens in a therapeutic peptide vaccine has 
since been used in clinical trials [7,8]. Alternatively, using comple-
mentary whole-exome sequencing, transcriptome sequencing analysis 
and mass spectrometry, immunogenic peptide vaccines can be formu-
lated, capable of generating T cell responses specifically to cancer cells 
and not healthy tissue [9,10]. Hence, peptide-based vaccine strategies 
that can induce durable immune responses are increasingly explored. 
Specificity derived from antigen is not sufficient; an adjuvant is needed 
to provide adequate immune stimulation in concert with the provided 
antigen [11]. While current approved adjuvants are successful in 
inducing protective antibody responses, generating T cell immunity has 
proven a much more difficult challenge [12]. Our understanding of T 
cell immune activation has significantly improved over the last decades, 
including the identification of dendritic cells as initiators of adaptive 
immune responses and the receptors they employ to recognize foreign 
particles and mediate immune activation [13]. Therefore, adjuvants 
aimed at inducing dendritic cell (DC) activation or antigens specifically 
targeting DCs may improve T cell immunity. 
While MHCI molecules needed for the induction of CD8 T cell re-
sponses typically present peptide of 8–10 amino acids long, vaccination 
with these short peptide has been shown to induce T cell dysfunction at 
the vaccination-site because of persistent antigen in non-antigen pre-
senting cells [14]. Instead, peptides need to be lengthened to the extent 
that MHCI loading only occurs in cells capable of internalizing material 
and presentation of processed peptide on MHCI to T cells, for example 
dendritic cells [14]. Therefore, synthetic long peptides containing 
disease-associated antigens have been preferred in vaccination strate-
gies against viral infections [15] and cancer [16,17]. 
In this study, we show increased T cell immunogenicity of synthe-
sized trimeric peptidic structures compared to single long peptides. To 
facilitate easy and reproducible synthesis, we design a chemical nano-
platform that facilitates the efficient conjugation of pre-synthesized 
peptides into trimeric structures termed Antigen MAtriX (AMAX). We 
show that AMAX combined with the prototypical adjuvant for peptidic 
vaccines, agonistic CD40, is synergistically enhanced by the clinically 
approved adjuvants MF59 (AddaVax). We also show that AMAX can be 
chemically modified with the DC-SIGN carbohydrate ligand, Lewis Y, to 
facilitate DC targeting to the endocytic receptor DC-SIGN and conse-
quently enhance the T cell-mediated immune response in human DC- 
SIGN transgenic mice. In a tumor setting, AMAX platform could 
accommodate several antigens, including neo-antigens, for combination 
therapy with for antagonistic PD1 antibody therapy. Finally, neo- 
antigen immunization reduced tumor growth in vivo. 
2. Material and methods 
2.1. Mice 
Mice transgenic for hDC-SIGN, OT-I and OT-II on the C57BL/6 
background were bred at the animal facility of VU University (Amster-
dam, Netherlands) under specific pathogen-free conditions and used at 
12–32 weeks of age. Mice transgenic for hDC-SIGN, OT-I and OT-II on 
the C57BL/6 background have been described previously [18–20]. Fe-
male and male mice were equally divided among groups, unless stated 
otherwise. All experiments were approved by the Animal Experiments 
Committee of the VU University and performed in accordance with 
national and international guidelines and regulations. 
2.2. Flow cytometry facilities and reagents 
All flow cytometry experiments were performed at the O2 Flow Fa-
cility at VU University (Amsterdam, Netherlands) using an X20 Fortessa 
flow cytometer (BD Biosciences) and ImageStreamX (Amnis Corp.) im-
aging flow cytometer. All antibodies were purchased from Biolegend, 
Miltenyi and eBioscience (ThermoFisher), specifically: anti-IFNγ (Clone 
XMG1.2), anti-TNFα (Clone TN3-19), anti-IL2 (Clone JES6-5H4), anti- 
CD44 (Clone IM7), anti-KLRG1 (Clone 2F1/KLRG1), anti-CD62L (Clone 
MEL-14), anti-CD4 (Clone GK1.5), anti-CD8 (Clone H35–17.2), anti- 
CXCR3 (Clone CXCR3-173), anti-CD11b (Clone M1/70), anti-B220 
(Clone RA3-6B2), anti-CD45 (Clone 30-F11), anti-CD3 (Clone 145- 
2C11), anti-MHCII (Clone M5/114.15.2), anti-CD16/32 (Clone 93), 
Fixable viability dye-eFluor 780 (Thermo Fisher). OVA257-264-H2-Kb-PE 
and GP100-H2-Kb-PE tetramers were a kind gift from Dr. J.W.Drijfhout 
at the LUMC, Leiden, Netherlands. 
2.3. Chemicals and peptide synthesis 
Chemicals were obtained from commercial suppliers and used 
without further purification. All Fmoc-amino acids and trifluoro acetic 
acid (TFA) were purchased from Novabiochem. Rink amide Chemmatrix 
resin, triisopropylsilane (TIS), Ethanedithiol (EDT), Triethylamine 
(TEA), Dimethylsulfoxide (DMSO) and diethyl ether were purchased 
from Sigma Aldrich. Piperidine, acetonitrile, N,N-dimethyl formamide 
(DMF) were purchased from Biosolve. All peptides were synthesized by 
solid phase peptide synthesis using Fmoc chemistry on a peptide syn-
thesizer (Protein Technologies Inc.) at the GlycO2pep unit. The peptides 
were purified on a preparative Ultimate 3000 HPLC system (Thermo 
Fisher) over a Vydac 218MS1022 C18 25  250mm column (Grace 
Davidson). Confirmation of purity and mass was achieved by the Ulti-
mate 3000 UHPLC system (Thermo Fisher) hyphenated with an LCQ- 
Deca XP Iontrap ESI mass spectrometer (Thermo Finnigan) via a RSLC 
120 C18 Acclaim 2.2 μm particle 2.1  250 mm column and sample 
ionization in positive mode. 
2.4. Peptide sequences 
OTI-OTII sequence: EEKSIINFEKLISQAVHAAHAEINEAGRKEEK, 
GP100-PADRE sequence: EEKKVPRNQDWLAKFVAAWTLKAAAKEEK, 
TRP1-TRP2 sequence: EEKCRPGWRGAACNQKISVYDFFVWLKEEK, 
MC38 neoantigen sequences Dpagt1-OTII: EEKSIIVFNLLISQAVHAA-
HAEINEAGRKEEK; Reps1-OTII: EEKAQLANDVVLISQAVHAAHAEI-
NEAGRKEEK; Adpgk-OTII: EEKASMTNMELMISQAVHAAHAE 
INEAGRKEEK; OTI-OTIII: EEKSIINFEKLEKLTEWTSSNVMEERKEEK 
2.5. Single chain synthetic long peptide and trimer 
The single chain synthetic long antigen peptides were synthesized 
completely on solid phase. After the synthesis of first arm, Fmoc-Lys 
(Fmoc)-OH was added to the peptidic chain to achieve branching. The 
synthesis proceeded simultaneously on both α and ε amino groups of 
“the core-lysine” to synthesize the second and third arm. The peptides 
were cleaved from the resin using a cleavage solution containing 92.5% 
TFA, 2.5% MilliQ, 2.5% TIS and 2,5% EDT. The peptides were collected, 
lyophilized and purified by HPLC. 
2.6. Single branched trimeric long peptidic conjugates; the Antigen Matrix 
(AMAX) 
To synthesize the AMAX-core 1 equivalent of Tris (2-aminoethyl) 
amine (5.45 mg, 37 μmoles) reacted with 3.2 equivalents of LC-SMCC 
((succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-ami-
docaproate), Thermo Scientific) (50 mg, 118 μmoles) in anhydrous 
DMSO. The reaction was incubated for 1 h at room temperature and 
purified over prepHPLC. The AMAX conjugates were generated by 
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conjugation of single arm peptides containing a C-terminal cysteine with 
the AMAX-core. Briefly, 4 equivalents of single arm peptide were added 
to AMAX-core in DMSO containing 50–100 mM TEA. After incubation 
for 1 h at room temperature the conjugates were purified over PrepHPLC 
and analyzed over mass spectometry. 
2.7. Murine bone marrow-derived and splenic CD11c dendritic cells 
Bone marrow-derived dendritic cells were cultured as described by 
Lutz et al. [21]. Splenic CD11c dendritic cells were isolated using a 
combination of enzymatic digestion and MACS sorting using the 
CD11c-magnetic isolation kit. In short, mice were sacrificed and the 
spleen isolated and cut small using sterile scissors in 385 μg/ml liberase 
TL (2WU) and incubated at 37 C for 20 min. Enzymes were deactivated 
using ice-cold RPMI 1640 complete (10% FCS, 1% 50 U/mL penicillin, 
50 μg/ml streptomycin, HEPES/EDTA). After digestion, cells were run 
through a 100 μm cell strainer and extensively washed before MACS 
sorting. Splenic CD11c dendritic cells were isolated using a 
CD11c-magnetic isolation kit according to manufacturer’s instructions 
(MagniSort™, eBioscience/ThermoFisher). Purity of CD11c cells was 
typically >96% of alive cells. 
2.8. Imaging flow cytometry and sample preparation (tumor cell killing 
assay) 
Spleens were harvested from vaccinated mice after prime-boost in-
jections with the reported product. Spleens were mechanistically dis-
rupted and filtered through a 70 μm cell strainer. Red blood cells were 
lysed using ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA), washed and counted before purification using MagniSort Mouse 
CD8-negative isolation kits according to manufacturer’s instructions 
(eBioscience/Thermo Fisher). Equal number of splenocytes from mice 
within a group were pooled before purification. After purification 
(typically >95% of alive cells), CD8 T cells were co-cultured with 
CFSE-labeled OVA-expressing GL26 glioblastoma cells for 18 h in a 
tumor/T cell ratio of 1:10, respectively. After co-culture, supernatant 
was harvested for interferon γ cytokine detection and the total cell 
culture was used for further imaging flow cytometry analysis. Next, the 
cells were stained with anti-CD8, Hoechst and fixable viability dye for 
30 min at 4 C. Cells were washed with PBS twice and fixed for 15 min 
using ice-cold 4% PFA. After washing twice, the fixed cells were resus-
pended in PBS. Cells were analyzed on the ImageStream X100 (Amnis- 
Merck Millipore) imaging flow cytometer as previously described (22). 
A minimum of 15,000 cells were acquired per sample. Analysis was 
performed with single cells after compensation (with a minimum of 
5000 cells). 
2.9. FACS acquisition and analyses 
All samples were acquired on an X20 Fortessa flow cytometer (BD 
Biosciences), of which the performance was checked and calibrated 
daily with CS&T beads (BD Biosciences). Detector voltage settings were 
set initially based on daily CS&T settings and only adjusted when fluo-
rescent signal was off-scale, with a maximum adjustment of 100 values. 
Aqcuisition of samples was done using the high throughput sampler 
(HTS), measuring samples at a max of 2.0 μL/second at an acquisition 
rate <15.000 events/second. After acquisition, samples were compen-
sated using fluorescently labeled beads and adjusted according to FMO 
experimental samples acquired within the same experiment. Gating 
strategies were based on a combination of FMO and expert gating 
knowledge. For tSNE unsupervised clustering analysis, compensated 
populations were concatenated and exported as FCS files per experi-
mental group using FlowJo 10 software and uploaded to the Cytobank 
online cloud-based flow cytometry platform (https://www.cytobank. 
org/). For the tSNE analysis in Fig. 2 an equal number of 4770 
antigen-specific CD8 T cells from peptide and trimer conditions was 
used for input (9540 total). Clustering was performed based on 
expression of KLRG1, CD127, CD62L and CD44 for 2000 iterations and a 
theta of 50. For the tSNE analysis in Fig. 7 an equal number 12049 
antigen-specific CD8 cells of each condition was used for input (36,147 
in total). Since all antigen-specific CD8 T cells from these conditions 
were CD44CD62L  , the expression of CD127, KLRG1 and CXCR3 for 
2000 iterations and a theta of 50 was used to cluster subpopulations. 
Data and statistics presented in bar graphs are expertly gated in FlowJo 
based on tSNE-aided gating strategies using all individual samples per 
experimental groups. 
2.10. Cytokine ELISA 
The cytokine IFNγ was determined in supernatant of tumor/T cell 
cocultures using a commercially available ELISA kit and performed ac-
cording to the manufacturer’s instructions (eBioscience 5017319). In 
short, NUNC ELISA plates were coated using IFNγ capture antibody in 1x 
coating buffer O/N. Wells were blocked using 1x ELISA diluent. Samples 
were incubated at RT for 2 h. Detection antibody was diluted in ELISA 
diluent and incubated for 1 h at RT. Avidin-HRP diluted in ELISA diluent 
was added to the wells and incubated for 30 min on RT. TMB solution 
was added till the standard was stained. The ELISA was stopped using 2 
N H2SO4. The plate was measured on a BioRad iMark microplate reader 
at 450 nm. 
2.11. Antigen presentation assays 
OTI and OTII transgenic mice were sacrificed and spleens were 
mechanistically disrupted and filtered through a 70 μm cell strainer. Red 
blood cells were lysed using ACK lysis buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA) and washed before purification using MagniSort 
Mouse CD4  or CD8-negative isolation kits according to manufacturer’s 
instructions (eBioscience/Thermo Fisher). Purified CD4 and CD8 T 
cells were labeled using 2 μM CFSE and counted before co-culture. 
BMDCs were pulsed with product at indicated concentrations in the 
presence of medium, 2 μg/ml MPLA or 2 μg/ml Poly I:C for 3 h. After 
extensive washing of the BMDCs, purified T cells were co-cultured for 3 
days at 37 C, stained and measured on an X-20 Fortessa flow cytometer. 
Proliferation results are calculated and represented as percentage 
responding T cells (‘calculated cells at the start of culture’/‘number of 
cells that went into division’*100). 
2.12. Vaccination 
Mice were subcutaneously vaccinated with synthetic long peptides, 
trimers or AMAX mixed with 25 μg of anti-CD40 in 1:1 PBS/AddaVax 
emulsion according to manufacturer’s instructions (InvivoGen) in a 
maximum volume of 100 μL. Synthetic long peptides were injected at a 
mass of 15 nmol and trimers or AMAX were injected at a mass of 5 nmol 
per mouse per injection. 
2.13. Isolation and analysis of leukocytes from the blood and spleen of 
vaccinated mice 
Mice were bled by cheek-pinch and approximately 100 μL of blood 
was collected in heparin-coated tubes. Red blood cells were lysed using 
ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) and 
washed before staining. Mice were sacrificed and spleens were mecha-
nistically disrupted and filtered through a 70 μm cell strainer. Red blood 
cells were lysed using ACK lysis buffer and washed before counting and 
subsequent staining protocols. Single cells suspensions from spleens and 
blood of vaccinated mice were incubated with OVA257-264-H2-Kb-PE or 
GP100-H2-Kb-PE tetramers together with CD8a PerCP for 45 min at 
room temperature. Cell were washed and incubated with other directly 
labeled primary antibodies before mild fixation with 2% PFA for 15 min 
at 4 C. 
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2.14. Ex vivo peptide restimulation and intracellular cytokine detection 
Single cell suspensions of spleens were counted and 3  106 cells 
were restimulated with short peptide for either 6 h (CD8 T cell 
restimulation) or 48 h (CD4 T cell restimulation) in the presence of 10 
μg/ml or 100 μg/ml cognate antigen (short peptide), respectively. The 
last 6 h of the restimulation was in the presence of 1 μg/ml Brefeldin A. 
Cells were harvested and first stained for CD8b or CD4 and fixable 
viability dye. Next, the stained cells were washed with PBS and fixed 
with 4% PFA in PBS for 15 min at 4 C. After fixation, the cells were 
permeabilized with 0,5% saponin in PBS/BSA 0,5% buffer for 15 min. 
Intracellular cytokines were subsequently stained with anti-IFNγ and 
anti-TNFα for 30 min at room temperature in 0,5% saponin PBS/BSA 
0,5% buffer. Finally, cell suspensions were acquired and analyzed using 
flow cytometry. 
2.15. In vivo anti-tumor immunization 
Mouse MC38 colorectal carcinoma tumor cells were cultured in 
DMEM up to 90% confluency in T75/T175 flasks before injection. Mice 
were anesthetized using 2% isoflurane, flanks were shaved and tumor 
cells in serum-free medium were subcutaneously injected in a volume of 
50 μL. Tumor size was measured using digital calipers every two days in 
a double-blind manner. Total tumor volume was calculated using for-
mula 4/3  π  abc (a width of the tumor/2, b  length/2 and c  the 
average of a and b). Mice were sacrificed when tumor exceeded 800 
mm3 or at the end of the study (day 23). Subcutaneous immunization in 
the neck was performed at day 7 after tumor cell injection, whereas 
treatment using antagonistic PD1 antibody (clone RMP1-14, in house, 
endotoxin free) was started at day 9 after tumor cell injection. 
2.16. Statistics 
Statistics were performed using GraphPad Prism 6 software. For the 
comparison of two groups a student’s t-test was used. For more than two 
groups a two-way analysis-of-variance (ANOVA) was used followed by a 
Tukey posthoc analysis to compare means between two groups. *P <
0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001, data represented as 
mean    SEM. 
3. Results 
3.1. Solid phase allows synthesis of antigenic long peptides and 
multivalent trimers for antigen presentation by dendritic cells 
Peptides are widely used in vaccination strategies to boost antigen- 
specific immunity. With efficient induction of T cell specific responses 
in clinical trials, in addition to low vaccine toxicity and high patient 
tolerance, these synthetic long peptides are fundamental components in 
immunotherapeutic strategies [22]. The synthesis of long peptides for 
the use of antigenic vaccine compounds is typically performed using 
liquid or solid phase synthesis using fluorenylmethyloxycarbonyl pro-
tecting group (Fmoc) chemistry. To study whether multivalent repre-
sentation of synthetic peptides would improve immune responses, we 
used this method to prepare single chain synthetic long peptides and 
single branched trimeric long peptide. The synthesis of the single chain 
synthetic long peptide is achieved via successive reactions of amino acid 
derivatives of the first peptide arm on resin. The synthesis of single 
branched trimeric long peptide involves the further elongation using 
lysine with an α and ε amino group. The two amino groups on the core 
lysine allows parallel extension of the peptide into a second and third 
branch, resulting in the formation of a peptidic trimer (Fig. 1A). We 
started off making use of OVA peptides as model antigens to compare 
Fig. 1. | Solid phase synthesis of linear long peptides and trimers produces products that can be processed and presented by (bone marrow-derived) 
dendritic cells to CD8 T cells in vitro. A. Long peptides were synthesized using solid phase peptide synthesis. Additionally, using a lysine with an α and ε 
amino group after the first peptide, the molecule is extended with a second and third branch simultaneously. This results in a trimer containing three peptides. B. 
Bone marrow-derived dendritic cells (BMDCs) were incubated with either 900 nM peptide or 300 nM trimer in the presence or absence of 2 μg/ml monophosphoryl 
lipid A (MPLA) or 10 μg/ml polyinosinic:polycytidylic acid (Poly I:C) for 3 h. After washing away the product and adjuvants, BMDCs were incubated with freshly 
purified CFSE-labeled CD8 T cells from OTI transgenic mice for 3 days. Cultures were harvested and proliferation of CD8 T cells was measured by dilution of CFSE. 
The percentage of OTI CD8 T cells that result in proliferation is increased by peptide and antigen matrix in an antigen-specific manner. Data (mean  SEM of 
biological triplicate) is representative of 2 independent experiments. 
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Fig. 2. | Trimers induce potent CD8 T cell responses with an effector phenotype and tumor cell killing capacity. A. Mice were subcutaneously vaccinated on 
day 0 (prime) and on day 14 (boost) with PBS, 15 nmol peptide or 5 nmol trimer with 25 μg agonistic CD40 antibody. Blood was collected on day 7 and spleen was 
collected after sacrificing the animals on day 21. B. A single dose of trimer induces significantly higher numbers of antigen-specific CD8 T cells. C. 7 days after the 
boost vaccination, the trimer still outperformed the peptidic form of the vaccine formulation. D. CD8 isolated from trimer-vaccinated mice showed polyfunctionality 
as demonstrated by the significantly higher number of single (IFNγ) and double (IFNγTNFα) producing CD8 T cells after peptide re-stimulation. E. tSNE un-
supervised clustering analysis of antigen-specific CD8 T cells identifies heterogeneity based on CD62L, CD44, KLRG1 and CD127 (expression as color code). The 
phenotype of isolated CD8 T cells from trimer-vaccinated mice is characterized by increased effector differentiation (CD62L  and KLRG1). F. CD8 T cells purified 
from splenocytes from vaccinated mice were pooled per group and cultured for 16 h with ovalbumin-expressing GL26 tumor cells. G. Purified CD8 T cells from 
trimer-vaccinated mice showed increased tumor killing capability compared to CD8 T cells from peptide-vaccinated mice as measured by imaging flow cytometry. 
H. Additionally, IFNγ production was increased after 16 h of T cell/tumor cell co-culture. Data (mean  SEM) is representative of 2 independent experiments with 
group size N  5/6. Statistics by one-way ANOVA with Tukey post-hoc multiple comparison test; *p < 0.05. (For interpretation of the references to color in this figure 
legend, the reader is referred to the Web version of this article.) 
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their efficacy in single and multivalent representation. 
Synthetic long peptides incorporating multiple antigens and flanking 
regions need to be enzymatically processed inside the cell for loading to 
MHC class I and –II complexes and presentation to T cells. To test 
whether the synthesized constructs are adequately processed and pre-
sented to T cells in an antigen-specific manner, we performed antigen 
presentation experiments in vitro. We generated bone marrow-derived 
dendritic cells (BMDCs), as previously described [21]. BMDCs were 
pulsed with peptide or trimer in concentrations with equal antigenic 
epitopes for 3 h. Co-culture with antigen-specific OTI CD8 T cells 
showed efficient internalization, processing and presentation to CD8 T 
cells (Fig. 1B). Interestingly, in conditions of increased adjuvanticity 
(with MPLA/Poly I:C) BMDCs pulsed with trimers outperformed those 
loaded with the synthetic long peptides (Fig. 1B). 
3.2. Multivalent trimeric constructs increase CD8 T cell immunity 
compared to single long peptides 
Having established the correct peptidic and trimeric structures for 
antigen presentation in vitro, we investigated the potency of these 
products to elicit de novo immune responses in a vaccination setting in 
vivo. The potency of the vaccine was tested in a typical prime-boost 
vaccination strategy including agonistic CD40 antibody as adjuvant 
(Fig. 2A). Seven days after the prime injection blood was isolated and 
the percentage of antigen-specific CD8 T cells was measured by flow 
cytometry. Using a SIINFEKL-H2-kb tetramer, we found that trimers 
induced higher numbers of antigen-specific CD8 T cells, compared to 
the synthetic long peptide (Fig. 2B). The vaccinated mice were then 
sacrificed 7 days after the second boost vaccination and the number and 
function of CD8 T cells was investigated. Similar to blood-derived 
lymphocytes after the prime vaccination, antigen-specific CD8 T cell 
numbers were significantly higher in number in mice vaccinated with 
trimers compared to the synthetic long peptides (Fig. 2C). Furthermore, 
by re-stimulation with short peptide and intracellular cytokine staining, 
a significantly higher number of CD8 T cells producing the effector 
cytokines TNFα and/or IFNγ was detected in mice vaccinated with tri-
mers (Fig. 2D). To show that the gain efficacy of the trimer is not due to 
its specific antigenic sequence, we generated peptides and trimers con-
taining an alternative CD4 T cell epitope and show that the trimer of 
this product also outperforms single peptides (Supplementary Figure 1). 
Next, we employed an unbiased tSNE unsupervised clustering analysis of 
the phenotype of antigen-specific CD8 T cells from vaccinated mice. 
Using the expression of CD62L, CD44, CD127 and KLRG1 to cluster the 
antigen-specific CD8 T cells into subsets (Fig. 2E). Interestingly, 
antigen-specific CD8 T cells isolated from the spleen after trimer prime- 
boost vaccination showed a higher frequency of antigen-specific CD8 T 
cells with an effector phenotype, as evidenced by the combined loss of 
CD62L and gain of KLRG1 expression (Fig. 2E). This suggests not only a 
quantitative increase in number, but also a qualitative difference be-
tween single and trimer peptidic vaccination. Finally, we investigated 
whether CD8 T cells from vaccinated mice were able to recognize and 
kill tumor cells expressing the antigen. We purified CD8 T cells from 
either peptide- or trimer-vaccinated mice using negative selection by 
magnetic isolation and co-cultured these cells with GL26 tumor cells 
expressing ovalbumin (Fig. 2F). After 16hr of co-culture, we harvested 
the tumor cells and measured cell death using imaging flow cytometry. 
Antigen-expressing GL26 tumor cells were more efficiently killed by 
CD8 T cells isolated from trimer vaccinated mice, compared to peptide 
vaccinated mice (Fig. 2G). These data were additionally reproduced 
using regular flow cytometry (data not shown). In parallel, the super-
natant of the tumor cell/CD8 T cell co-culture from trimer-vaccinated 
mice contained high amounts of the T cell effector cytokine IFNγ 
(Fig. 2H), suggesting that CD8 T cells isolated from trimer vaccinated 
mice can recognize and kill GL26 tumor cells. 
3.3. The antigenic MAtriX (AMAX) core allows the generation of pre- 
synthesized peptides into AMAX trimers 
Next, we aimed to synthesize trimers containing other antigenic 
epitopes, including the melanoma antigen GP100, which is more chal-
lenging than OVA, due to its lower solubility. However, solid phase 
synthesis depends on the continued elongation of single amino acids to a 
growing peptide chain. As a result, some amino acid sequences are less 
efficiently coupled or reduce peptide solubility, further reducing yield 
and purity of the product. Due to incomplete addition in each reaction, 
the purity decreases exponentially with the elongation of every amino 
acid. Considering the length of the single branched trimeric long peptide 
chain, a low purity can be expected [23]. This is evidenced by the HPLC 
fractionation and subsequent mass spectrometry of trimers containing 
GP100 epitopes, but also holds for the peptide chains with the OTIOTII 
epitopes (Fig. 3A). To circumvent low purity, we designed a nanoplat-
form that enables conjugation of pre-purified synthetic long peptides 
into a multivalent conjugate. This trimeric structure remains soluble, 
increases purity and yield during synthesis without compromising the 
tertiary structure from trimeric structures. Key to this peptidic conjugate 
is the core. By reacting a Tris (2-aminoethyl)amine with three equiva-
lents of LC-SMCC, a flexible core was constructed achieving multivalent 
presentation of single long peptides upon conjugation (Fig. 3B). This 
results in a highly stable conjugation platform for efficient synthesis of a 
trimeric peptidic structure we have termed Antigenic MAtriX (AMAX; 
Fig. 3B). This synthesis significantly aids HPLC purification and in-
creases yield, while deriving a cleaner product for both the OTIOTII and 
the GP100 conjugates (Fig. 3C). 
3.4. AMAX induces CD8 and CD4 T cell activation in vivo, 
outperforming single peptides 
First, to assess the functionality of the synthesized AMAX product, 
we tested antigen presentation by CD11c splenic dendritic cells 
(Fig. 4A). Splenic DCs pulsed with peptide or AMAX both induced the 
proliferation of antigen-specific CD8 T cells (Fig. 4B) and CD4 T cells 
(Fig. 4C). Peptide-pulsed splenic DCs were slightly better at inducing 
CD4 T cell proliferation compared to AMAX. Addition of innate stimuli 
like Poly I:C or MPLA in the pulsing phase did not affect antigen pre-
sentation to either CD8 T cells or CD4 T cells in these conditions 
(Fig. 4B/C). To test the efficacy of AMAX to generate CD8 T cell re-
sponses in vivo, we vaccinated mice with either peptides or AMAX 
containing similar amounts of antigenic epitopes (Fig. 4D). Seven days 
after a single dose of AMAX with agonistic CD40 antibody, we detected a 
significant increase in antigen-specific CD8 T cells in blood (Fig. 4E). A 
boost vaccination, 14 days after the prime injection, resulted in similar 
increased efficacy of AMAX inducing antigen-specific CD8 T cell re-
sponses in the spleen, outperforming single peptides (Fig. 4F). Re- 
stimulation of splenocytes derived from vaccinated mice with the 
cognate peptide and intracellular cytokine measurements revealed sig-
nificant increases of polyfunctional CD8 T cells producing the effector 
cytokines IFNγ, TNFα and IL2 (Fig. 4G). Because the synthetic long 
peptides and AMAX were both able to induce CD4 T cell proliferation in 
vitro, we additionally investigated the induction of antigen-specific 
CD4 T cells by peptide re-stimulation and intracellular cytokine 
staining. While not statistically significant, AMAX induce higher levels 
of antigen-specific CD4 T cells compared to single peptides (Fig. 4H). 
3.5. The MF59 (AddaVax) adjuvant synergistically boosts AMAX/ 
αCD40 vaccine efficacy 
Even though agonistic CD40 has previously been shown to boost 
CD8 T cell responses as adjuvant in peptidic vaccines [24,25], we 
sought to investigate whether agonistic CD40 antibody could be 
replaced or combined with the widely used adjuvant MF59 (commer-
cially available as AddaVax). As such, we vaccinated mice with either a 
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Fig. 3. | Chemical nanoplatform facilitates highly efficient conjugation of pre-synthesized peptides into an Antigenic MAtriX (AMAX) with increased 
purity, yield and solubility A. Solid phase synthesis inherently hampers the construction of trimers and reduces purity, yield and solubility. HPLC fractionation and 
mass spectrometry profiles reveal that solid phase synthesis of difficult to synthesize peptides result in poor purity and therefore low yield. B. A chemical nano-
platform for conjugation of pre-synthesized long peptides can be made by reacting a Tris (2-aminoethyl)amine with three equivalents of LC-SMCC. C. Subsequent 
conjugation of pre-purified synthetic long peptide to the nanoplatform results in an antigenic matrix (AMAX) with increased purity and yield. Data shown are 
representative of at least three individual batches of synthesized product. 
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single injection of AMAX with agonistic CD40, AddaVax or the combi-
nation of both. Seven days after a single injection, re-stimulation of 
splenocytes by either CD8 or CD4 reactive peptides, revealed induction 
of both CD8 T cells and CD4 T cells (Fig. 5A and B, respectively). 
While agonistic CD40 increased the levels of antigen specific CD8 and 
CD4 T cells (as previously shown), AddaVax only induces moderate 
levels of antigen-specific CD4 T cells, without induction of 
antigen-specific CD8 T cells. Surprisingly, AddaVax combined with 
agonistic CD40 boosts AMAX-induced antigen-specific CD8 and CD4
T cells in a synergistic manner (Fig. 5A–B). Having established the po-
tency of combined adjuvancy of agonistic CD40 antibody in 
combination with AddaVax, we investigated whether AMAX still out-
performs single peptides in a classical prime-boost vaccination scheme 
(Fig. 5C). Indeed, after a prime-boost vaccination strategy AMAX com-
bined with agonistic CD40 and AddaVax outperforms synthetic long 
peptides in terms of antigen-specific CD8 T cells (Fig. 5D). Peptide 
re-stimulation of splenocytes and intracellular cytokine staining shows 
similar induction of significantly higher number of CD8 T cells pro-
ducing effector cytokines IFNγ and TNFα. (Fig. 5E). While not signifi-
cant, peptide re-stimulation shows slightly higher numbers of 
cytokine-producing CD4 T cells in the AMAX immunized group 
(Fig. 5F). 
Fig. 4. | AMAX induces potent CD8 T cell responses in vitro and in vivo A. Splenic CD11c DC were MACS sorted from enzymatically digested spleens and 
pulsed with 900 nM long peptide or 300 nM AMAX in the presence of medium, 2 μg/ml MPLA or 10 μg/ml Poly I:C for 3 h. After washing away the product and 
adjuvants, BMDCs were incubated for 3 days with freshly purified CFSE-labeled CD8 or CD4 T cells from OTI or OTII transgenic mice, respectively. Proliferation of 
responding T cells was assessed by flow cytometry B. Both peptide and AMAX products were able to induce proliferation of antigen-specific CD8 T cells by splenic 
DCs. The adjuvants did not affect the % of responding CD8 T cells in this setting. C. Proliferation of antigen-specific CD4 was induced by both peptide and AMAX 
products, although peptide D. Mice were subcutaneously vaccinated on day 0 (prime) and on day 14 (boost) with PBS, 15 nmol peptide or 5 nmol AMAX with 25 μg 
agonistic CD40 antibody. Blood was collected on day 7 and spleen was collected after sacrificing the animals on day 21. E. 7 days after the first vaccination antigen- 
specific CD8 T cells are significantly higher in the AMAX-vaccinated group. F. After the boost, AMAX-vaccinated mice still show significantly increased antigen- 
specific CD8 T cells. G. CD8 T cells from AMAX-vaccinated mice are polyfunctional as evidenced by the single (IFNγ) and double (IFNγTNFα) cytokine 
production after peptide re-stimulation. H. Although not statistically significant, AMAX induce higher levels of antigen-specific CD4 T cells compared to single 
peptides. Data (mean  SEM) is representative of at least two independent experiments with group size N  9/10. Statistics by one-way ANOVA with Tukey post-hoc 
multiple comparison test; *p < 0.05 **p < 0.01. 
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3.6. Functionalizing the AMAX platform with the DC-SIGN ligand Lewis 
Y targets dendritic cells for increased T cell responses 
Next, dendritic cells are critical drivers of adaptive immune re-
sponses and have therefore been explored as targets for vaccination 
[26]. Therefore, we explored the AMAX platform as a vector delivery 
platform to target dendritic cells. More specifically, by chemically 
conjugating the carbohydrate Lewis Y to the terminal peptidic arms of 
the AMAX, the resulting AMAX:Lewis Y is hypothesized to bind the 
dendritic cell-specific C-type lectin receptor DC-SIGN (Fig. 6A) [27], and 
facilitate processing and presentation of AMAX-including antigens. 
Using ELISA, we successfully verified intact Lewis Y on the AMAX 
platform and confirmed the capacity of human DC-SIGN to bind AMAX: 
Lewis Y using recombinant hDC-SIGN Fc (Fig. 6B). Consequently, to 
investigate the effect of targeting DC-SIGN expressed by dendritic cells 
in vivo, we vaccinated transgenic mice that express human DC-SIGN 
(hDC-SIGN) driven by the CD11c-promoter. As a result, dendritic cells 
specifically express human DC-SIGN in these mice [18]. Vaccination 
using AMAX:Lewis Y with only agonistic CD40 antibody resulted in 
increased frequencies of antigen-specific CD8 T cells compared to un-
modified AMAX in two independent experiments (Fig. 6C). After 
prime-boost vaccination, splenocytes from vaccinated mice were 
restimulated with short peptide and intracellular cytokine production 
was measured. A higher frequency of cytokine-producing CD8 and 
CD4 T cells was observed when AMAX was functionalized with the 
DC-SIGN binding ligand, Lewis Y (Fig. 6D). To test whether AddaVax 
retained the synergistic augmentation of αCD40 in this setting, we 
primed mice with one injection of AMAX:Lewis Y/αCD40 with either 
PBS, the TLR4-activator monophosphoryl lipid A (MPLA) or AddaVax 
(Fig. 6E). The frequency of antigen-specific CD8 T cells was highly 
increased when AddaVax was used, compared to αCD40 alone or even in 
combination with MPLA (Fig. 6E). Peptide restimulation of splenocytes 
from vaccinated mice showed that the synergistic effect of AddaVax was 
most pronounced in the CD8 T cell compartment in this setting 
(Fig. 6F). To further investigate the effect of AddaVax on the phenotype 
of antigen-specific CD8 T cells, we used tSNE unsupervised clustering. 
Since all antigen-specific CD8 T cells in these conditions were 
CD62L  CD44, we used CD127, KLRG1 and CXCR3 to cluster (Fig. 6G). 
AddaVax-adjuvanted AMAX:Lewis Y/αCD40 vaccine combinations 
showed significant enrichment of antigen-specific KLRG1 terminally 
differentiated effector CD8 T cells (Fig. 6H). Hence, by targeting the 
AMAX directly to DC-SIGN on dendritic cells in vivo, an even more 
Fig. 5. | AMAX with the adjuvant MF59 (AddaVax) synergistically boosts agonistic CD40 antibody adjuvanticity A. Vaccinating mice with a single dose of 
AMAX with either agonistic CD40 antibody or AddaVax or the combination affects the induction of antigen-specific CD8 T cells. Combining the adjuvants syn-
ergistically boosts the CD8 T cell response, with significantly higher amounts of double-producing (IFNγTNFα) CD8 T cells after peptide re-stimulation. B. The 
combination of agonistic CD40 and AddaVax induces the highest level of antigen-specific CD4 T cells. C. After establishing the best combination of adjuvants, a 
prime-boost vaccination strategy with agonistic CD40 and AddaVax was performed. D. This revealed AMAX as superior in inducing antigen-specific CD8 T cells 
compared to single peptides as measured by tetramer staining. E. Re-stimulation with peptides and intracellular cytokine staining shows that antigen-specific CD8
and CD4 T cells (F.) are enriched in AMAX-vaccinated mice. Data (mean  SEM) is representative of at least two independent experiments with group size N  9/10. 
Statistics by one-way ANOVA with Tukey post-hoc multiple comparison test, A,B,E,F statistics on total %cytokine-producing cells; *p < 0.05 **p < 0.01 ***p < 0.001 
****p < 0.0001. 
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potent antigen-specific CD8 and CD4 T cell immune response can be 
elicited. 
3.7. Incorporation of tumor-associated self-antigens into AMAX leads to 
increased de novo CD8 and CD4 T cell responses 
Finally, we investigated the efficacy of AMAX to induce antigen- 
specific CD8 T cell responses to tumor-associated self-antigens like 
GP100, TRP1 and TRP228  30. We generated synthetic long peptides and 
AMAX harboring the CD8 T cell-reactive GP100 epitope and the pan 
HLA-DR (PADRE) CD4 T cell-reactive epitope [31]. A single injection 
of GP100-PADRE AMAX with the AddaVax/αCD40 adjuvant combina-
tion induced de novo antigen-specific CD8 T cell responses to the GP100 
epitope as measured using GP100-H2-kb tetramers (Fig. 7A). Peptide 
Fig. 6. | AMAX modified with DC-targeting ligands can further improve antigen delivery and adaptive immune responses during prime-boost vaccination 
strategies A. OTI-OTII AMAX constructs can be chemically modified with the DC-SIGN carbohydrate ligand, Lewis Y. B. The presence of intact Lewis Y was verified 
by ELISA, as well as the capacity to bind human DC-SIGN using recombinant hDC-SIGN Fc. C. The frequency of antigen-specific CD8 T cells after prime (day 7 
blood) and boost (day 21 spleen) injections is higher in mice vaccinated with Lewis Y-modified AMAX compared to unmodified AMAX. D. Peptide re-stimulation of 
splenocytes from vaccinated mice show enhanced cytokine-producing CD8 T cells and CD4 T cells using with Lewis Y-modified AMAX compared to unmodified 
AMAX. E. Using single injection prime vaccination, AddaVax shows synergistic augmentation of AMAX:Lewis/αCD40 vaccines compared to PBS or the TLR4-stimulus 
monophosphoryl lipid A (MPLA). F. Peptide restimulation of splenocytes from vaccinated mice shows comparable increases in IFNγ-producing CD8 T cells by 
AddaVax. CD4 T cell activation after peptide restimulation was also boosted, although this was similar to MPLA. G. Unsupervised clustering of antigen-specific 
CD44CD62L  CD8 T cells by tSNE using CD127, KLRG1 and CXCR3 shows significant different phenotypes of T cells induced by different adjuvants. H. Quan-
tification shows a significant enrichment of KLRG1high CD8 T cells in the vaccination group containing AddaVax. ELISA data (mean  -SEM of experimental 
triplicate) representative of at least 2 different batches of product. In vivo data (mean  SEM) representative of 2 independent experiments with group size N  10 for 
C/D and N  5 for G-H. Statistics by one-way ANOVA with Tukey post-hoc multiple comparison test, D,F statistics on total %cytokine-producing cells; *p < 0.05 **p 
< 0.01 ***p < 0.001 ****p < 0.0001. 
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re-stimulation combined with intracellular cytokine staining was less 
sensitive, but a similar trend was evident (Fig. 7B). Although no dif-
ference in numbers was observed between the peptide and AMAX 
vaccinated condition, PADRE-specific CD4 T cells were also efficiently 
induced (Fig. 7C). Next, we explored peptidic constructs containing the 
melanoma-associated TRP1 CD8 T cell-reactive and TRP2 CD4 T 
cell-reactive epitope. Since we did not possess TRP1 or TRP2 detecting 
tetramers, vaccination efficacy with these products was measured using 
peptide restimulation and intracellular cytokine staining. With these 
constructs, only AMAX induced TRP1-specific CD8 T cell responses 
(Fig. 7D), as well as, CD4 T cell responses (Fig. 7E). 
The prevalence of somatic mutations among human cancers has been 
shown to drive immunogenicity due to the presence of mutated “non- 
self” antigens, called neoantigens [9]. These patient-specific neo--
antigens are increasingly being identified and used as anti-tumor vac-
cine component [10,32]. As such, we synthesized peptides and AMAX 
versions of previously identified neoantigens specific for MC38 mouse 
tumor cells [9] (Fig. 7F). By combining the CD8 T cell-specific MC38 
neoantigens with the OTII CD4 T cell-specific antigen, we could test the 
universality of the AMAX platform in a vaccination and anti-tumor 
setting. The AMAX platform induced significantly higher frequencies 
of neoantigen-specific CD8 T cells after a single prime immunization 
(Fig. 7G). Also, the frequency of OTII-specific CD4 T cells increased, 
although this was not statistically significant. Finally, to investigate the 
anti-tumor capacity of the AMAX platform, we designed a clinically 
relevant setting of anti-tumor vaccination which includes a regiment of 
PD1 immune checkpoint blockade (ICB; Fig. 7I). First, mice were sub-
cutaneously inoculated with MC38 tumor cells for 7 days, after which 
palpable tumors were established and mice were immunized with PBS, 
the mix of peptides or the mix of AMAX constructs. Two days later, PD1 
ICB was started three times per week in all groups. Interestingly, six days 
after the immunization (T  13) the effect of neo-antigen immunization 
became apparent, which continued until the end of the study (Fig. 7J). 
Importantly, the immunization with the AMAX neoantigen constructs 
significantly reduced tumor growth in this setting (Fig. 7K). 
Fig. 7. | Tumor-specific AMAX immunization enhances anti-tumor immunity A. GP100-PADRE constructed AMAX with agonistic CD40 and AddaVax induces 
antigen-specific CD8 T cells after a single s.c. vaccination. B–C. Peptide re-stimulation of splenocytes from vaccinated mice reveal low, but detectable levels of 
GP100-specific CD8 T cells (B.) and PADRE-specific CD4 T cells (C.). TRP1-TRP2 constructed AMAX induced antigen-specific CD8 and CD4 T cells as evidenced 
by cytokine-producing CD8 (D.) and CD4 T cells (E.) after peptide re-stimulation. F. CD8-reactive neoantigens from the MC38 murine colorectal carcinoma were 
synthesized as peptides and AMAX, including the OTII CD4 epitope. G. Percentage cytokine-producing CD8 T cells after peptide restimulation after mice subcu-
taneously immunized with the peptide or AMAX mix, in combination with agonistic CD40/AddaVax. H. Percentage cytokine producing CD4 T cells after peptide 
restimulation. I. Mice were subcutaneously inoculated with MC38 tumor cells. 7 days after tumor cells injection, mice were immunized with PBS, peptide mix or 
AMAX mix containing neoantigens. 2 days later, antagonistic PD1 therapy started three times a week until end of study. J. Experimental groups were divided and 
tumor growth measured starting with moment of immunization (T  7). K. Quantification of the growth curve (average increase in tumor size) per individual tumor/ 
mouse shows significantly decreased tumor growth in the immunized groups. A–E: Data (mean  SEM) is representative of two independent experiments with group 
size N  9/10. G/H: Data (mean  SEM) with a group size of N  8. J/K: Combined data (mean  SEM) from two independent experiments with group size N 
10–12. Statistics by one-way ANOVA with Tukey post-hoc multiple comparison test, B-E and G,H statistics on total %cytokine-producing cells; *p < 0.05 **p < 0.01 
***p < 0.001 ****p < 0.0001. 
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4. Discussion 
We have shown that formulating a peptide vaccine into a multivalent 
trimer containing CD8 T cell epitopes and CD4 T cell epitopes can 
induce antigen-specific CD8 and CD4 T cell activation in vitro and in 
vivo. In a classical prime-boost vaccination strategy, trimers out-
performed single peptides in terms of antigen-specific CD8 T cell fre-
quency, cytokine production after peptide restimulation and effector 
phenotype. As a result, recognition of tumor cells expression the cognate 
antigen by CD8 T cells isolated from mice vaccinated with trimers, 
resulted in IFNγ production and tumor cell death. In our attempt to 
synthesize several other trimers using solid phase synthesis with changes 
in hydrophobicity, we noticed poor yield and difficulty to purify the 
trimers. Linear synthetic peptides are generally synthesized by Fmoc 
chemistry, based on sequential addition of amino acids to extend the 
product. This was mainly due to the increased length of the complex 
trimer. The length of the synthetic peptide is limited by several factors, 
including the reaction yield or aggregation-prone sequences [23]. As a 
result, reagents are lost and the more side products are generated, the 
more troublesome it becomes to purify the target product by 
high-performance liquid chromatography (HPLC). To overcome this 
inefficient production, we have developed a chemical nanoplatform that 
facilitates highly efficient conjugation of pure pre-synthesized peptides, 
resulting in a product termed Antigen MAtriX (AMAX). This procedure 
facilitates production of trimers with high yield and purity, while 
maintaining the trimeric structure and increased immunogenicity. It 
additionally maximizes the applicability of peptidic constructs in the 
clinic [23]. 
In terms of therapeutic effect, vaccination of mice with AMAX 
combined with anti-CD40 increased the frequency of antigen-specific 
CD8 T cells. Since the discovery that ligation of the CD40 receptor 
on antigen presenting cells boosts the priming of CD8 T cells [33,34], 
agonistic CD40 antibody has been shown a potent adjuvant in several 
peptide vaccines [24,35,36]. Importantly, the use of agonistic CD40 
antibody has now been shown to mediate potent anti-tumor immunity 
without active vaccination [37–40], especially in combination with 
checkpoint inhibitors like antagonistic PD1 antibody [41]. This provides 
additional rationale to combine peptide vaccination with agonistic 
CD40 antibody as a therapeutic strategy against tumors. In the current 
study, we sought to improve the cellular response induced by 
anti-CD40/AMAX vaccination through a combination with well char-
acterized and clinically-approved adjuvants. MF59 (AddaVax) is a 
clinically approved squalene oil-in-water adjuvants used in seasonal 
influenza vaccines for over 20 years [42,43]. Surprisingly, AMAX did 
not induce antigen-specific CD8 T cells when combined with AddaVax 
alone. However, both CD4 and CD8 T cell responses were synergis-
tically boosted to high frequency by the combination of anti-CD40 and 
AddaVax. It is known MF59 induces the formation of germinal center 
responses and consecutive high affinity antibody production by B cells 
[44,45]. However, the augmentation of both CD8 and CD4 T cell 
responses by AddaVax in combination with anti-CD40 is a completely 
novel finding. Not only does this combination increase the frequency of 
antigen-specific T cells, it also highly promotes the differentiation to 
antigen-specific CD62LlowKLRG1high CD8 T cells. This phenotype of 
CD8 T cell has been suggested to represent terminally differentiated 
effector T cells responsible for protective immunity [46,47]. This func-
tional effective phenotype of CD8 T cells is suggested by the thera-
peutic anti-tumor experiments, although tumor rejection was not 
complete. The functional distinction between terminal differentiation 
and plasticity of CD8 T cells is currently hotly debated and unclear 
[48]. By unbiased analysis we have described the differences in phe-
notypes of vaccine-generated antigen-specific CD8 T cells, which show 
a surprising susceptibility to adjuvant selection. Two independent 
studies have shown that CD62L  effector CD8 T cells expressing high 
levels of KLRG1 can dedifferentiate into memory T cells capable of 
long-term protective immunity [49,50]. How adjuvant selection and 
AMAX vaccination affects the spatiotemporal distinction between 
effector and memory function or quantity and quality is beyond the 
scope of the current study, but an interesting challenge to address in 
future studies. 
How AddaVax specifically augments the αCD40/AMAX vaccine re-
mains to be defined. Since KLRG1 expression on CD8 T cells is regu-
lated by T-bet upon antigen recognition and IL-12 production [51], it is 
likely the phenotype induced by AddaVax is influenced by dendritic 
cells. Several findings might implicate monocyte-derived dendritic cells 
(moDCs) in this observation. First, MF59 has been shown to promote the 
attraction and differentiation of monocytes to moDCs [52–54]. Sec-
ondly, the in vivo efficacy of MF59 depends on the intact MyD88 
signaling [55] and moDCs can become the main IL-12 producers under 
inflammatory conditions in a MyD88-dependent manner [56]. Addi-
tionally, DC-SIGN has been often used as the primary marker for moDCs 
[57,58] and effectively targeted in this study and others [59–61]. 
However, it remains to defined specifically how the synergy between 
agonistic CD40 and MF59 (AddaVax) is orchestrated. 
Since professional antigen presenting cells like dendritic cells are key 
in initiating adaptive immunity, targeting antigens to dendritic cells has 
been proposed as a viable vaccination strategy [62–64]. Dendritic cells 
express several pattern recognition receptors that are inherently capable 
of binding foreign antigen and facilitating uptake and antigen presen-
tation to T cells [62]. DC-SIGN (Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin) is one such receptor that 
facilitates the uptake of glycosylated pathogens by dendritic cells for 
antigen presentation to T cells [65,66]. By conjugating DC-SIGN-binding 
glycans to antigens, vaccination efficacy can be increased [61]. As such, 
we show that targeting Lewis Y-modified AMAX to dendritic cells, the 
cellular immune response is significantly boosted in hDC-SIGN trans-
genic mice. 
Precise mechanistic insight into the success of trimers over peptides 
remains to be investigated. In our in vitro studies using BMDCs or splenic 
CD11c DCs, we could not discern a significant benefit of trimers over 
peptides. This suggests that the enhanced immunogenicity of AMAX 
constructs is dependent on the in vivo setting and possibly does not 
involve the construct-DC interface, but instead bioavailability at the 
injection site or in the draining lymph node. Also, differences between 
larger particulate antigens and soluble have been suggested to critically 
affect immunogenicity in vaccines [67]. Both synthetic long peptide of 
approx. 3500kD and [28.], [29.], [30.] AMAX products of 12000kD are 
soluble and do not form visual aggregates in our hands, regardless of the 
incorporated antigenic peptide sequence. Also, the surface charge or 
zeta potential of drug delivery systems have been shown to affect the 
biological availability and in vivo mode of action [68]. However, the 
different AMAX products comprise different amino acid sequences and 
therefore different zeta potentials. Regardless of these differences in 
charge, the AMAX outperformed single peptides in terms of cellular 
immunity, suggesting the zeta potential is of minor consequence in our 
immunization strategies. Hence, the functional difference in mechanism 
of action between peptide and AMAX occur in vivo on a molecular scale 
that warrants further investigation. 
As our understanding of the immune system increases, the approach 
to rational vaccine design changes. In an era where technological ad-
vancements are increasing the potential of precision medicine, the 
possibility of antigen discovery, synthesis of highly defined peptidic 
vaccines and need for T cell-mediated vaccines are tied together. Since 
the revolution of immunotherapeutic in cancer, the interest for dendritic 
cell-mediated immune responses have spiked. Therefore, clearly defined 
improvements of peptide-based vaccination strategies aimed at using 
dendritic cells in situ are of increasing importance. Importantly, we show 
the incorporation of neoantigen, as well as tumor-associated antigens, 
into AMAX constructs capable of inducing de novo T cell responses. 
Importantly, therapeutic immunization with neoantigen AMAX con-
structs reinforced PD1 ICB in a syngeneic mouse tumor model. In a 
therapeutic clinical setting, neo-antigen-containing AMAX vaccination 
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may complement existing immune responses that can be unleashed by 
antagonistic PD1 antibody with de novo generated immune responses by 
AMAX. Also, in none of the in vivo experiments did we encounter un-
warranted internal or external pathological side effects, suggesting a 
favorable safety profile. In summary, we provide a clearly defined 
peptide-based vaccination strategy capable of generating high quality 
CD8 and CD4 T cell responses for immunotherapeutic purposes. 
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